A coronavirus vaccine being developed at the University of Oxford is safe and induces an immune response to the disease, the first phase of human trials has revealed.
Doses of the vaccine, called AZD1222, were given to 1,077 healthy adults aged between 18 and 55 in five UK hospitals in April and May.
The results – published in The Lancet journal on Monday – show they induced strong antibody and T-cell immune responses for up to 56 days after they were given.
T-cells are crucial for maintaining protection against the virus for years.
Scientists found the response could be even greater after a second dose of the vaccine.